TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
RS Herbst, D Prager, R Hermann, V Miller… - Journal of Clinical …, 2004 - ascopubs.org
7011 Background: Tarceva™(erlotinib) is a potent reversible HER1/EGFR tyrosine kinase
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer
RS Herbst, D Prager, R Hermann… - Journal of clinical …, 2005 - ascopubs.org
Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2004 - ascopubs.org
7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …
inhibitor with single-agent antitumor activity and has shown additive effects when added to …
Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status …
R Lilenbaum, R Axerold, S Thomas… - Journal of Clinical …, 2006 - ascopubs.org
7022 Background: A previous CALGB trial suggested a benefit for carboplatin-paclitaxel
(CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low …
(CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low …
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2007 - ascopubs.org
Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy …
FA Shepherd, J Pereira, TE Ciuleanu… - Journal of Clinical …, 2004 - ascopubs.org
7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by …
C Gridelli, F Ciardiello, R Feld, CA Butts… - Journal of Clinical …, 2010 - ascopubs.org
7508 Background: In a placebo-controlled trial, E prolonged survival of unselected aNSCLC
patients (pts) not eligible for further chemotherapy. Two phase II studies suggested that first …
patients (pts) not eligible for further chemotherapy. Two phase II studies suggested that first …
The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC)
H Groen, OG Arrieta, H Riska, K Horwood… - Journal of Clinical …, 2008 - ascopubs.org
19000 Background: Erlotinib significantly improved survival and quality of life while delaying
symptom progression compared with placebo in patients (pts) with relapsed NSCLC …
symptom progression compared with placebo in patients (pts) with relapsed NSCLC …
Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: sub-group analysis of …
VA Miller, R Herbst, D Prager… - Journal of Clinical …, 2004 - ascopubs.org
7061 Background: Erlotinib (Tarceva) is a potent HER1/EGFR tyrosine kinase inhibitor (TKI).
Monotherapy trials of EGFR-TKIs have suggested never smokers and pts with …
Monotherapy trials of EGFR-TKIs have suggested never smokers and pts with …
[HTML][HTML] Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2
PJ Hesketh, K Chansky, AJ Wozniak, FR Hirsch… - Journal of Thoracic …, 2008 - Elsevier
Purpose This phase II study (S0341) evaluated the efficacy and tolerability of single-agent
erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung …
erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung …
相关搜索
- erlotinib hcl carboplatin and paclitaxel
- phase iii trial of erlotinib
- lung cancer paclitaxel chemotherapy
- lung cancer erlotinib hydrochloride
- lung cancer therapy in patients
- lung cancer cisplatin and gemcitabine
- paclitaxel chemotherapy erlotinib hydrochloride
- performance status agent erlotinib
- erlotinib hcl long survival
- performance status standard chemotherapy
- performance status randomized phase
- performance status oncology group
- standard chemotherapy agent erlotinib
- randomized phase agent erlotinib
- standard chemotherapy randomized phase
- erlotinib in combination cisplatin and gemcitabine